AR073452A1 - Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis - Google Patents

Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis

Info

Publication number
AR073452A1
AR073452A1 ARP090102491A ARP090102491A AR073452A1 AR 073452 A1 AR073452 A1 AR 073452A1 AR P090102491 A ARP090102491 A AR P090102491A AR P090102491 A ARP090102491 A AR P090102491A AR 073452 A1 AR073452 A1 AR 073452A1
Authority
AR
Argentina
Prior art keywords
leishmania
antigens
leishmaniasis
diagnosis
treatment
Prior art date
Application number
ARP090102491A
Other languages
English (en)
Inventor
Ajay Bhatia
Steven G Reed
Original Assignee
Infectious Disease Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Inst filed Critical Infectious Disease Res Inst
Publication of AR073452A1 publication Critical patent/AR073452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)

Abstract

Además se provee un polinucleotido que codifica el péptido de fusion, un anticuerpo, una composicion farmacéutica, una vacuna y un método para detectar la infeccion asintomática o subclínica por Leishmania. Reivindicacion 1: Un polipéptido de fusion aislado que comprende dos o más antígenos de Leishmania seleccionados del grupo que consiste de K26, K39, y K9, o sus porciones inmunogénicas o sus variantes, en donde al menos uno de los antígenos se aísla de Leishmania donovani.
ARP090102491A 2008-07-03 2009-07-02 Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis AR073452A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7825508P 2008-07-03 2008-07-03

Publications (1)

Publication Number Publication Date
AR073452A1 true AR073452A1 (es) 2010-11-10

Family

ID=41066370

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102491A AR073452A1 (es) 2008-07-03 2009-07-02 Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis

Country Status (8)

Country Link
US (3) US8231881B2 (es)
EP (1) EP2291394B1 (es)
CN (1) CN102083853B (es)
AR (1) AR073452A1 (es)
BR (1) BRPI0913972B1 (es)
ES (1) ES2628743T3 (es)
PT (1) PT2291394T (es)
WO (1) WO2010003085A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710155A2 (pt) 2006-04-10 2011-08-23 Infectious Disease Res Inst Inc compostos e métodos para diagnóstico e tratamento de leishmaniose
US8425919B2 (en) * 2008-05-21 2013-04-23 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
CN102083853B (zh) 2008-07-03 2014-09-17 传染性疾病研究院 融合蛋白及其在利什曼病的诊断和治疗中的用途
US9814331B2 (en) * 2010-11-02 2017-11-14 Ember Technologies, Inc. Heated or cooled dishware and drinkware
EP2756850A1 (en) * 2013-01-18 2014-07-23 Philipps-Universität Marburg Diagnosis of Leishmania infection
ES2728865T3 (es) 2013-03-28 2019-10-29 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
KR20220100041A (ko) 2013-12-31 2022-07-14 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 단일 바이알 백신 제형
WO2016055836A1 (pt) * 2014-10-09 2016-04-14 Universidade Federal De Minas Gerais - Ufmg Processo de produção e uso da proteína rk39-kddr e kit para diagnóstico de leishmaniose
TWI766942B (zh) * 2017-02-13 2022-06-11 美商海科生醫有限責任公司 透過利用瞬態和穩態間隔振動移液管來混合流體或介質的設備和方法
BR102019003639A2 (pt) * 2019-02-22 2021-11-16 Fundação Oswaldo Cruz Proteína quimérica, seu método para produção e uso, bem como molécula de ácido nucleico, cassete de expressão, vetor de expressão, célula hospedeira, composição para diagnóstico de leishmaniose, kit de diagnóstico de leishmaniose e método de diagnóstico de leishmaniose in vitro
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
AU2021406131A1 (en) 2020-12-23 2023-08-03 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
EP4215916A1 (de) * 2022-01-20 2023-07-26 Philipps-Universität Marburg Test zum nachweis von antikörpern gegen leishmanien

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197062B1 (fr) 1984-10-01 1991-01-09 Institut Pasteur Anticorps monoclonaux anti-leishmania, hybridomes secreteurs de ces anticorps, antigenes de leishmania reconnus par ces anticorps, procede d'obtention et applications de ces anticorps monoclonaux et de ces antigenes
IL82740A0 (en) 1987-06-01 1987-12-20 Yeda Res & Dev Assay for leishmaniasis
FR2619220B1 (fr) 1987-08-03 1993-03-26 Pasteur Institut Antigenes specifiques de leishmania et leur procede de preparation, profils antigeniques contenant ces antigenes et leur application au diagnostic des leishmanioses viscerales.
US5304371A (en) 1992-02-14 1994-04-19 Lasys Corporation Peptide for diagnosing and immunizing against T. cruzi infection
US5411865A (en) 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
PT716697E (pt) 1993-09-03 2003-08-29 Univ Mcgill Genes e proteinas de leishmania expressos diferencialmente
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6013268A (en) 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
US5879687A (en) 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
WO1995029239A2 (en) 1994-04-22 1995-11-02 Corixa Corporation Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
US5965142A (en) 1995-08-04 1999-10-12 Corixa Corporation Polypeptides and methods for the detection of L. tropica infection
US6365165B1 (en) 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6500437B1 (en) 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6613337B1 (en) 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US5834592A (en) 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6638517B2 (en) 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6375955B1 (en) 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6607731B1 (en) 1995-09-22 2003-08-19 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6054135A (en) 1996-11-14 2000-04-25 Corixa Compounds and methods for the detection and prevention of T. cruzi infection
US6228372B1 (en) 1997-04-15 2001-05-08 Corixa Corporation Compounds and methods for the detection and prevention of T. cruzi infection
US5744593A (en) 1996-02-15 1998-04-28 Heska Corporation Parasitic helminth larval thiol specific antioxidant proteins and nucleic acid molecules
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US5846748A (en) 1996-11-15 1998-12-08 The Council Of Scientific & Industrial Research Method for diagnosing visceral leishmaniasis in a patient by identification of a new key marker namely 9-O-acetylated sialoglycoconjugate
EP0981624A2 (en) 1997-02-12 2000-03-01 Corixa Corporation $i(LEISHMANIA) ANTIGENS FOR USE IN THE THERAPY AND DIAGNOSIS OF LEISHMANIASIS
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
BRPI0710155A2 (pt) 2006-04-10 2011-08-23 Infectious Disease Res Inst Inc compostos e métodos para diagnóstico e tratamento de leishmaniose
BRPI0815565A2 (pt) 2007-07-13 2015-02-18 Infectious Disease Res Inst Composições de esterol 24-c-metiltransferase de leishmania para a prevenção, tratamento e diagnóstico de leishmaniose.
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US8425919B2 (en) 2008-05-21 2013-04-23 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
CN102083853B (zh) 2008-07-03 2014-09-17 传染性疾病研究院 融合蛋白及其在利什曼病的诊断和治疗中的用途
ES2859673T3 (es) 2010-11-08 2021-10-04 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
US20160158329A1 (en) 2013-03-28 2016-06-09 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
ES2728865T3 (es) 2013-03-28 2019-10-29 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis

Also Published As

Publication number Publication date
BRPI0913972B1 (pt) 2018-06-26
CN102083853A (zh) 2011-06-01
BRPI0913972A2 (pt) 2014-09-30
US20150017200A1 (en) 2015-01-15
US8231881B2 (en) 2012-07-31
US8771710B2 (en) 2014-07-08
EP2291394B1 (en) 2017-03-15
ES2628743T3 (es) 2017-08-03
US20100008924A1 (en) 2010-01-14
WO2010003085A1 (en) 2010-01-07
PT2291394T (pt) 2017-06-05
US9279005B2 (en) 2016-03-08
US20130071862A1 (en) 2013-03-21
CN102083853B (zh) 2014-09-17
EP2291394A1 (en) 2011-03-09

Similar Documents

Publication Publication Date Title
AR073452A1 (es) Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
CL2013003248A1 (es) Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto.
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CO2018009434A2 (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue
CO6260094A2 (es) Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
AR112480A1 (es) Composiciones de glp-1 y sus usos
ECSP15014133A (es) Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
BRPI0518146A (pt) kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
AR065523A1 (es) Procedimiento para fomentar una respuesta inmunitaria frente a un patogeno y composiciones
AR073170A1 (es) Vacunas de poliproteinas recombinantes para el tratamiento y diagnostico de leishmaniasis
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
AR061894A1 (es) Vacunas para malaria
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
AR057720A1 (es) Dispersiones acuosas y su uso
BR112015003785A2 (pt) vírus, vacina, teste de diagnóstico para distinguir mamíferos vacinados com uma vacina, e, uso de um teste de diagnóstico
AR071741A1 (es) Vacunas contra la malaria
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee